![](/images/graphics-bg.png)
A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting
Joint Authors
Kim, Ka-Rham
Kang, Gaeun
Ki, Myung-Seo
Shim, Hyun-Jeong
Hwang, Jun-Eul
Bae, Woo-Kyun
Chung, Ik-Joo
Kim, Jong-Keun
Jeong, Seongwook
Cho, Sang-Hee
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-09-03
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Purpose.
This study was conducted to determine the optimal dose titration of ramosetron to prevent the Rhodes Index of Nausea, Vomiting, and Retching (RINVR).
Methods.
Patients treated with folic acid, 5-fluorouracil, and oxaliplatin were randomized into three groups (0.3 mg, 0.45 mg, and 0.6 mg ramosetron before chemotherapy).
The pharmacokinetics and pharmacodynamics using RINVR were evaluated.
Results.
Seventeen, 15, and 18 patients received ramosetron at doses of 0.3 mg, 0.45 mg, and 0.6 mg, respectively.
Tmax (h), Cmax (ng/mL), and AUClast (ng·h/mL) were associated with dose escalation significantly, showing a reverse correlation with the RINVR during chemotherapy.
Acute CINV was observed in four patients (22.2%), two patients (14.3%), and one (5.6%) patient and a delayed CINV on day 7 was found in eight (47%), three (21.4%), and five (27.8%) patients in each group.
The complete response rate was increased with dose escalation (35.3%, 50.0%, and 72.2% in each group) and also showed the tendency for decreasing moderate-to-severe CINV.
Conclusions.
This study shows a trend regarding the dose-response relationship for ramosetron to prevent CINV, including delayed emesis.
It suggested that dose escalation should be considered in patients with CINV in a subsequent cycle of chemotherapy, and an individual approach using RINVR could be useful to monitor CINV.
American Psychological Association (APA)
Kim, Ka-Rham& Kang, Gaeun& Ki, Myung-Seo& Shim, Hyun-Jeong& Hwang, Jun-Eul& Bae, Woo-Kyun…[et al.]. 2015. A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting. BioMed Research International،Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1055808
Modern Language Association (MLA)
Kim, Ka-Rham…[et al.]. A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting. BioMed Research International No. 2015 (2015), pp.1-7.
https://search.emarefa.net/detail/BIM-1055808
American Medical Association (AMA)
Kim, Ka-Rham& Kang, Gaeun& Ki, Myung-Seo& Shim, Hyun-Jeong& Hwang, Jun-Eul& Bae, Woo-Kyun…[et al.]. A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1055808
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1055808